NewAmsterdam Pharma officer sells 40,000 shares
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported a combination of option exercises and share sales involving the company’s ordinary shares.
Rhea-AI Filing Summary
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported a combination of option exercises and share sales involving the company’s ordinary shares. On June 22, 2026, she exercised options to acquire a total of 40,000 ordinary shares through two transactions of 15,000 and 25,000 shares at exercise prices of $11.90 and $10.90 per share, respectively.
On the same date, she executed open-market sales totaling 40,000 ordinary shares in two transactions: 39,700 shares at $30.20 per share and 300 shares at a weighted average price of $30.73, with individual trade prices ranging from $29.73 to $30.72 per share. Following these transactions, her direct holdings continue to include 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 40,000 shares ($757K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Kooij Louise Frederika
Role
Chief Accounting Officer
Sold
40,000 shs ($1.21M)
Approx. gross sale proceeds
$1.21M
Approx. exercise cost
$451K
Approx. pre-tax spread
$757K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option (right to buy) | 25,000 | $0.00 | $0.00 |
| Exercise | Option (right to buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 25,000 | $10.90 | $273K |
| Exercise | Ordinary Shares | 15,000 | $11.90 | $179K |
| Sale | Ordinary Shares | 39,700 | $30.20 | $1.20M |
| Sale | Ordinary Shares | 300 | $30.73 | $9K |
Holdings After Transaction:
Option (right to buy) — 78,134 contracts (Direct);
Ordinary Shares — 24,353 shares (Direct)
Footnotes (4)
- F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F2. Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
- F3. The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
- F4. The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Key Figures
Shares sold: 40,000 shares
Sale price (large block): $30.20 per share
Weighted average sale price: $30.73 per share
+5 more
8 metrics
Shares sold
40,000 shares
Ordinary shares sold in open-market transactions on June 22, 2026
Sale price (large block)
$30.20 per share
Price for 39,700 ordinary shares sold
Weighted average sale price
$30.73 per share
300-share sale; trades ranged from $29.73 to $30.72
Options exercised
40,000 shares
15,000 and 25,000 options exercised into ordinary shares
Option exercise price 1
$11.90 per share
Exercise price for 15,000 options on ordinary shares
Option exercise price 2
$10.90 per share
Exercise price for 25,000 options on ordinary shares
Unvested RSUs
22,000 ordinary shares
Subject to restricted stock unit awards and vesting conditions
Option expiration dates
2033-01-01 and 2033-05-18
Expiration dates for the exercised option grants
Key Terms
weighted average price, restricted stock unit, exercise or conversion of derivative security, option (right to buy), +1 more
5 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock unit financial
"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
option (right to buy) financial
"security_title: Option (right to buy)"
vesting financial
"shares underlying the option vest on the one-year anniversary of vesting start date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did NewAmsterdam Pharma (NAMS) report for Louise Frederika Kooij?
Louise Frederika Kooij reported exercising options for 40,000 ordinary shares and selling 40,000 ordinary shares on June 22, 2026. The activity combined option exercises at lower strike prices with open-market sales at around $30 per share.
What option exercises did the NewAmsterdam Pharma (NAMS) Form 4 disclose?
The filing shows two option exercises converting 40,000 options into ordinary shares. Kooij exercised 15,000 options at $11.90 per share and 25,000 options at $10.90 per share, turning previously granted derivative awards into directly held ordinary shares.
Does Louise Frederika Kooij still hold NewAmsterdam Pharma (NAMS) equity after these transactions?
Yes. Her direct holdings continue to include 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. These RSUs represent ongoing equity exposure tied to future service and vesting conditions rather than immediate, freely tradable shares.
What does the weighted average price disclosure mean in the NewAmsterdam Pharma (NAMS) Form 4?
The weighted average price of $30.73 reflects many small trades between $29.73 and $30.72. The insider notes a willingness to provide full detail on each individual trade to the issuer, its security holders, or SEC staff upon request, as is common in such disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
